Novalung (system of extracorporal membrane oxygenation)

2020: Announcement

At the end of February, 2020 the Fresenius company submitted the Novalung system which in whole or in part replaces the medical ventilator, pumping over the patient's blood through an oksigenator for ensuring gas exchange.

According to developers, Novalung is the first system of extracorporal membrane oxygenation (EKMO) capable to support gas exchange more than six hours in a row. The company is going to begin sales of a system in the USA in the middle of 2020.

Fresenius released the Novalung system replacing the medical ventilator

Novalung is extremely important stage in development of the means capable to support function of heart and lungs for a long time, - the president of Fresenius Medical Care in North America Mark Costanzo noted. - We made use of all experience accumulated when developing devices for treatment of diseases of kidneys to improve standards of therapy at sharp respiratory and warm and pulmonary insufficiency.

The Novalung system passed to Fresenius as a result of acquisition of Xenios company in 2016. Novalung does not require the high speed of a blood-groove therefore it uses rather small cannulas comparable to the system of dialysis. Fresenius claims that the products Novalung can replace in whole or in part traditional invasive mechanical ventilation, having reduced thereby ghost effects. A system can provide any level of oxygenation at sharp respiratory insufficiency, i.e. it can be adapted to individual needs of each patient.

Use of the pressure sensor in a system provides continuous monitoring and exact control of gas structure, and long-term, effective solution in the form of EKMO gives to seriously ill patients to patients time and support which are so necessary for treatment — doctor Robert Bartlett, honored professor of Medical school of the University of Michigan considers.[1]

Notes